Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Auto-Injector — Net revenue

Other product segments

Subtotal dosage forms
$417.92M+1.1%
Oral solid
$171.1M-4.4%
Subtotal therapeutic classes
$133.27M+23.1%
Distribution
$89.15M-15.0%
Central nervous system
$83.38M+23.3%
Transdermal
$73.96M+71.8%
Government label
$59.95M+19.6%
Injectable
$49.94M+43.5%
Other dosage forms
$46.61M-17.4%
Hormonal / allergy
$35.93M+5.1%
Biosimilar
$22.3M-21.9%
Other therapeutic classes
$13.95M+115%
Oral liquid
$12.09M-48.6%
Institutional
$9.82M-10.8%
International
$5.32M+331%

Similar metrics at other companies

Viatris logo
VTRSEpiPen® Auto-Injectors — Net Sales
$101.1M+4.6%
Baxter International logo
BAXInjectables & Anesthesia — Net Sales
$301M-10.1%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
AbbVie logo
ABBVEpkinly — Net revenues
$83M+62.7%
TFX
TFXInterventional — Net revenues
$204.66M+104%
ST
STAutomotive — Net revenue
$524.8M-0.8%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×—
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s auto-injector — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s auto-injector — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported auto-injector — net revenue of $41.91M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s auto-injector — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s auto-injector — net revenue decreased by 13.0% year-over-year, from $48.16M to $41.91M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s auto-injector — net revenue?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s auto-injector — net revenue has grown at a 18.3% compound annual growth rate (CAGR), from $140.56M to $232.8M.
What does auto-injector — net revenue mean?
This metric represents the total net revenue generated from the sale of epinephrine auto-injector products within the company's specialty pharmaceutical portfolio. It reflects the market demand and commercial performance of this specific medical device, accounting for gross sales adjusted for returns, rebates, and other sales deductions. Tracking this revenue stream provides insight into the company's competitive position within the critical care and emergency medicine market segments.